IFNG and myasthenia gravis: In this study, we analysed a cohort of patients with MS, NMOSD and MG treated with anti-CD20 therapy, compared with healthy controls, to evaluate the impact of rituximab or ocrelizumab therapy on the efficacy of the SARS-CoV-2 mRNA vaccine in eliciting humoral and cellular immunity, measured by detection of specific antibodies against the spike protein and release of interferon-gamma (IFN-γ) after spike protein stimulation of blood cells, respectively.